PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Alpha Lipoic Acid

Drugs in development · updated 30 October 2026

Alpha Lipoic Acid: clinical trials and development status

Other names and codes: Thioctic Acid

NLM verified identityNot approved in the USNo EMA authorisationEstimated launch Dec 2027 – Oct 2028 (Phuturdex estimate)

As of 30 October 2026 Alpha Lipoic Acid is in 12 active clinical trials (recruiting or ongoing, phases I–III) for 9 diseases. The most advanced phase is III.

12Active trials
IIIMost advanced phase
9Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Alpha Lipoic Acid and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Beta thalassemiaIII1NCT07157722
Colorectal neoplasmII–III1NCT07736495
InflammationII–III1NCT07736495
Knee osteoarthritisIII1NCT07399743
StomatitisII–III1NCT07736495
Insulin resistanceII1NCT05713799
Non-small-cell lung carcinomaII1NCT07574684
ObesityII1NCT05713799
Polycystic Ovary SyndromeII1NCT07182526

Everything on Alpha Lipoic Acid

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch